Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
Related Tickers: AQST
TL;DR
AQST filed a routine 8-K, no major news.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on December 19, 2024, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Aquestive Therapeutics is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not disclose any new material information that would inherently increase risk.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of Report
- 0001398733 (company_id) — Central Index Key
- 30 Technology Drive Warren, NJ 07059 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of December 19, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is December 19, 2024.
What is the state of incorporation for Aquestive Therapeutics, Inc.?
Aquestive Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Aquestive Therapeutics, Inc.?
The principal executive office address is 30 Technology Drive, Warren, NJ 07059.
Does this 8-K filing disclose any new material events or financial results?
Based on the provided text, this 8-K filing appears to be a routine report and does not explicitly disclose any new material events or specific financial results beyond the standard reporting categories.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-19 08:02:50
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20241219.htm (8-K) — 28KB
- aqstorphandrugdesignatio.htm (EX-99.1) — 16KB
- aqstorphandrugdesignatio001.jpg (GRAPHIC) — 271KB
- aqstorphandrugdesignatio002.jpg (GRAPHIC) — 235KB
- aqstorphandrugdesignatio003.jpg (GRAPHIC) — 193KB
- aqstorphandrugdesignatio004.jpg (GRAPHIC) — 273KB
- aqstorphandrugdesignatio005.jpg (GRAPHIC) — 145KB
- 0001628280-24-051956.txt ( ) — 1709KB
- aqst-20241219.xsd (EX-101.SCH) — 2KB
- aqst-20241219_lab.xml (EX-101.LAB) — 21KB
- aqst-20241219_pre.xml (EX-101.PRE) — 12KB
- aqst-20241219_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On December 19, 2024, Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") issued a press release announcing the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity to Libervant (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity ( i.e ., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy between two to five years of age. On April 26, 2024, Libervant (diazepam) Buccal Film was approved for pediatric patients between two to five years of age. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated December 19, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 19, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer